Mucopolysaccharidoses type IVA (Morquio disease) is a rare, autosomal recessive lysosomal storage disease that causes both obstructive and restrictive airway pathology, with respiratory failure being the primary cause of death. This article provides original data on the longitudinal characterization of pulmonary function changes in children with Mucopolysaccharidoses (MPS) IVA by presenting the data and nuanced trends of changes from sequential spirometry and oximetry. The sample size included 16 subjects, 13 had undergone enzyme replacement therapy (ERT), three had not undergone ERT treatment. A total of 180 individual plots are presented for spirometry variables (FEV1, FEV1 [%Pred] FVC, FVC [%Pred] and FEV1/FVC), 6MWT and oximetry variables (median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 [%]); over a nine-year period at a single quaternary paediatric metabolic centre. This data has been made public and has utility to clinicians and researchers due to the following: [1, 2] by providing the first comprehensive report of detailed changes in
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Mucopolysaccharidoses type IVA (Morquio disease) is a rare, autosomal recessive lysosomal storage disease that causes both obstructive and restrictive airway pathology, with respiratory failure being the primary cause of death. This article provides original data on the longitudinal characterization of pulmonary function changes in children with Mucopolysaccharidoses (MPS) IVA by presenting the data and nuanced trends of changes from sequential spirometry and oximetry. The sample size included 16 subjects, 13 had undergone enzyme replacement therapy (ERT), three had not undergone ERT treatment. A total of 180 individual plots are presented for spirometry variables (FEV1, FEV1 [%Pred] FVC, FVC [%Pred] and FEV1/FVC), 6MWT and oximetry variables (median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 [%]); over a nine-year period at a single quaternary paediatric metabolic centre. This data has been made public and has utility to clinicians and researchers due to the following: [1, 2] by providing the first comprehensive report of detailed changes in pulmonary function in children with MPS IVA, with and without ERT; [1e3] as well as changes in pulmonary function following the institution of non-invasive ventilation (NIV) and adenotonsillectomy. The data presented is related to the research article by Kenth et 
Data
We present original data from a retrospective, longitudinal, repeated-measures cohort study, where descriptive statistics and non-parametric correlation were performed for demographic, respiratory function and oximetry (sleep studies) variables over a study period from January 2009 to December 2018. Composite clinical endpoints used in this study for evaluating pulmonary function included spirometry variables (FEV 1 , FEV 1 [%Pred] FVC, FVC [%Pred] and FEV1/FVC), 6MWT and oximetry variables (median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 [%]). The data are supplemental to our study "The Characterization of Pulmonary Function in Patients with Mucopolysaccharidoses IVA: A Longitudinal Analysis" by Kenth et al. [1] .
Baseline demographics
Thirteen children underwent ERT, whereas the non-ERT arms had 3 children. The median age at diagnosis was 34 months (range: 14e161; IQR 62.75). The Presenting symptoms included: difficulty walking (7) , gibbus deformity (4), kyphoscoliosis (1) and chest-wall deformity (1) . Consanguinity of parents was present in 12.5 [2/16] of patients. The median age of commencing ERT was 78 months (IQR 77.5; 10th percentile 38.4, 90th percentile 179.8). The study included 44% of males (7/16) and 56% of females (9/16). The following patterns of genetic abnormalities were present (see Table 1 Table 1 illustrates the baseline demographics, including age at diagnosis, gender, parental consanguinity, what the presenting symptom was, the genetic mutation identified, the date when ERT therapy commenced (if applicable). Data are also presented on the age at first spirometry and oximetry, the presence of obstructive sleep apnoea, whether the patients had undergone an adenotonsillectomy and the institution on non-invasive, bilevel positive pressure ventilation (BIPAP).
Macroglossia was present in 44% of patients ( Cardiac disease, as assessed by echocardiography was normal in 62.5% (10/16) of patients, pathology delineated included, a small patent ductus arteriosus (PDA) in 6.3% (1/16), small PDA, mild tricuspid regurgitation (TR) in 6.3% (1/16), physiological mitral (MR) in 6.3% (1/16), physiological TR þ MR in 6.3% (1/16), dysplastic mitral and aortic valve in 6.3% (1/16).
Value of the Data
The data presented are the first comparison of enzyme replacement therapy (ERT) and non-ERT treated, in terms of the long-term decline in pulmonary function. The data is grounded from longitudinal, standardized, repeated measurements taken from spirometry and oximetry studies.
The data is the first to report on the long-term changes in pulmonary function after an intervention such as non-invasive ventilation (NIV) and adenotonsillectomy. These data are useful to clinicians and researchers evaluating the safety and efficacy of ERT on children with MPS IVA, especially within the context of evaluating airway respiratory changes. Table 2 summarises the median values, range and the overall trend for the changes in pulmonary function for each of the following variables: FEV1, FEV1 [%predicted], FVC, FVC [%predicted], FEV1/FVC ratio and the six-minute walking test (6MWT). Figs. 1e6 illustrate the data for each subject as longitudinal trajectories over time. Each graph is clearly labelled with the metric being assessed as well as the subject from which the data was obtained from. Linear regression was calculated where appropriate and the R 2 and intercept (y) were also recorded. Table 3 illustrates the median values, range and the overall trend for the changes in oximetry. These included data for median %Spo2, ODI 3%, mean nadir 3%, ODI 4%, mean nadir 4% and min dip SpO2 (%). Figs. 7e12 illustrate the individual plots for each subject (labelled) over time. As above, linear regression was calculated where appropriate and the R 2 and intercept (y) were also recorded.
Spirometry data

Oximetry data
Experimental design, materials, and methods
MPS IVA is associated with severe, debilitating airway and respiratory disease [1, 2] . The methodology employed to assess pulmonary function in this study is validated by and aligned to The American Thoracic Society [3, 4] and the British Thoracic Society guidance. The methodology used for oximetry as Fig. 1 . Forced expiratory volume in 1 second (FEV1) changes. The above graphs demonstrates each of the individual plots where constructed to ascertain the changes in pulmonary function over time for the given variable. The starting timepoint in the ERT group was shortly after ERT therapy had commenced. Data points are in blue and a line of best fit creating a regression line was created to ascertain the overall trend of whether there was a decline or improvement. For each of the regression curve the intercept and R 2 value is sated under the curve. Note also, the solid red and orange bars, that mark when a therapeutic intervention was undertaken. The solid vertical, red line (¡) indicates when adenotonsillectomy was undertaken and the orange line (¡) illustrates when NIV was instituted. There was incomplete data for some individuals, as adenotonsillectomy was undertaken prior to formal diagnosis and thus full lung function tests would not of been undertaken at the time. Subjects A to M were ERT treated and data recorded was post commencing ERT therapy; subjects N and O were not ERT treated and data was recorded after diagnosis. 6 . Six minute walk test (6MWT). The above graphs demonstrates each of the individual plots where constructed to ascertain the changes in pulmonary function over time for the given variable. Data points are in blue and a line of best fit creating a regression line was created to ascertain the overall trend of whether there was a decline or improvement. Note also, the solid red and orange bars, that mark when a therapeutic intervention was undertaken. The solid red line (À) indicates when adenotonsillectomy was undertaken and the orange line (À) illustrates when NIV was instituted. 
